EP4110379A1 - Method for obtaining of an antitumor composition, an antitumor composition and its use - Google Patents
Method for obtaining of an antitumor composition, an antitumor composition and its useInfo
- Publication number
- EP4110379A1 EP4110379A1 EP21712408.0A EP21712408A EP4110379A1 EP 4110379 A1 EP4110379 A1 EP 4110379A1 EP 21712408 A EP21712408 A EP 21712408A EP 4110379 A1 EP4110379 A1 EP 4110379A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fraction
- bacteria
- suspension
- mycobacterium bovis
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 17
- 239000000725 suspension Substances 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 241000186366 Mycobacterium bovis Species 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 238000002604 ultrasonography Methods 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 230000000771 oncological effect Effects 0.000 claims abstract description 8
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 210000000056 organ Anatomy 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000003708 ampul Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 4
- 210000003800 pharynx Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 abstract description 6
- 210000000170 cell membrane Anatomy 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 abstract description 3
- 210000002421 cell wall Anatomy 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 210000003705 ribosome Anatomy 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 238000002483 medication Methods 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000004807 localization Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- WEMFUFMJQFVTSW-UHFFFAOYSA-N compositin Natural products CC=C(C)C(=O)OC1CC(O)C2(C)COC3C2C1(C)C1CCC2(C)C(CC=C2C1(C)C3OC(=O)C(C)=CC)c1ccoc1 WEMFUFMJQFVTSW-UHFFFAOYSA-N 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Definitions
- the present invention relates to a method for obtaining of an antitumor composition from BCG vaccine, as well as to a composition with antitumor activity on the basis of BCG vaccine and use for prophylaxis and treatment of oncologic diseases thereof.
- EP 1 881 838 B1 discloses a method for preparing an antitumor composition by mixing two fractions obtained from a standard BCG vaccine containing Mycobacterium bovis, where fraction ⁇ containing live bacteria and obtained as a standard BCG vaccine containing 500 pg dried substance, is suspended in 1 mi of distilled water by first dilution of the suspension with saline solution or distilled water to a concentration from 100 to 10pkg/ml BCG, and second dilution of the suspension with saline solution to a concentration from 10 to 0,001 pkg/ml BCG, and fraction 2 is obtained by addition of standard solution of BCG vaccine to distilled water and additional dilution with saline solution, then the obtained suspension is treated with ultrasound for 8 - 12 minutes, allowed to stay at temperature of 4 - 8°C for 2 to 60 days, preferably 2 to 20 days, and then it is filtered. Both fractions are mixed in a
- the obtained composition is used for preparation of a medication for treatment of massive tumors, cancer of: throat, breast, stomach; liver, urinary bladder, colon, skin, as well as brain tumors, malignant melanoma and metastases of these cancers in all systems of the human body
- the problem to be solved is the development of a method for preparation of an antitumor composition on the basis of BCG vaccine intended for treatment of oncologic diseases, with lower toxicity for better tolerance by the patients where the prepared composition possessing at least a similar antitumor activity with the live vaccine, and capable to ensure the obtaining of preparations with controlled impact of effect, which provide the possibility for selection of a suitable agent for the individual need of the patient.
- this problem is solved by a method for preparation that includes the mixing of three fractions - fraction 1 containing live bacteria Mycobacterium bovis from BCG vaccine, fraction 2 consisting of suspension of killed bacteria Mycobacterium bovis from BCG vaccine, and fraction 3 that is a filtrate of a suspension of Mycobacterium bovis bacteria from BCG vaccine, destroyed by ultrasound, the fraction quantities being in a proportion of 1 : 10 : 100 volumetric units.
- the first stage of the present method is the obtaining of fraction 1 by dissolution of a standard ampoule of BCG vaccine in a standard solvent, additional dilution of the obtained suspension with saline solution or distilled water to a concentration of 100 to 10 pg/ml and a second dilution to a concentration of 10 to 0,001 pg/ml, following by preparation of fraction 2 through the heat treatment of a standard BCG vaccine, which is diluted with saline solution or distilled water to a concentration of 100 to 0,01 pg/ml and preparation of fraction 3 by dilution of a standard BCG vaccine with 3 to 5ml of saline solution or 4 to 6 ml of distilled water and treatment-of the suspension by ultrasound for 8 to 12 min, then the resulting suspension is remained for 2 to 60 days, preferably for 2 to 20 days at a temperature of 4 - 8°C, and then it is filtered.
- Another subject of the present invention is an antitumor composition obtained by the method that comprises fraction 1 with live bacteria Mycobacterium bovis, fraction 2 consisting of a suspension of killed bacteria Mycobacterium bovis and fraction 3 containing a filtrate of a suspension of destroyed by ultrasound cells of Mycobacterium bovis bacteria in a volumetric proportion of 1 : 10 : 100, which contains not only live and killed bacteria but also parts of bacteria, bacterial cell walls, inner cytoplasmic membrane, enzymes, ribosomes, bacterial nuclei, wax D, proteins, carbohydrates, lipids and nucleic acids.
- composition use obtained by the method for preparation of a medicinal composition, intended for treatment of oncologic diseases that affect different organs and systems in the human body.
- the composition is especially suitable for prophylaxis of the occurrence of oncologic diseases in predisposed individuals and for prophylaxis to prevent recurrence.
- the advantage of the method according to the present invention is that it ensures the obtaining of medications with differentiated impact of effect and allowing adequate dosing,
- the composition obtained by this method demonstrates lower toxicity because of the low content of live bacteria and unexpectedly higher therapeutic effect than the already known composition .
- One standard ampoule of BCG vaccine containing 500 pg of dried substance is suspended in 1ml of distilled water, the resulting suspension is diluted with saline solution to a concentration of 100 pkg/ml, then additionally is diluted by saline solution to reach a concentration of 10 pkg/ml.
- the content of living cells is controlled.
- Resulting fraction 1 contains in ddition to living cells, products of their vital activity and metabolites.
- a standard ampoule of BCG vaccine is dissolved in saline solution or distilled water to a concentration of 100 pg/ml and subjected to heat treatment at 125° C and 1 ,5 atm for 20min.
- Fraction 2 contains in addition to killed bacteria, products of their vital activity, parts of cells, and metabolites.
- Standard ampoule of BCG vaccine is suspended in a standard solvent the resulting suspension is diluted with 3 ml of saline solution and treated with ultrasound for 8 min, then left to stay in a refrigerator at a temperature of 4 - 8° C for 48 hours. Control for the existence of live bacteria during the 1 st and the 2 nd day is made.
- the resulting suspension is further filtered through a sterile filter Falcon with ⁇ 0,1 mm pore size.
- the obtained filtrate contains substances released by the cell during cell membrane destruction such as bacterial parts, bacterial cell walls, inner cytoplasmic membrane, enzymes, ribosomes, bacterial nuclei, carbohydrates, lipids and nucleic acids.
- the resulting three fractions are mixed in a volumetric ratio, respectively 5 : 50 : 500
- fraction 1 -proceed in the manner described in example 1 ,; where the resulting suspension is diluted in advance to a concentration of 50 pkg/ml and then to 0,1 pkg/ml.
- fraction 2 - Preparation of fraction 2 - proceed as in example 1, the working concentration is 11 m g/ml.
- fraction 3 - Preparation of fraction 3 - proceed in the manner described in example 1 , where the standard ampoule of BCG vaccine is dissolved with a standard solvent and the resulting suspension is diluted with 4 ml of distilled water. The resulting suspension is further treated by ultrasound for 9 min and left to stay in a refrigerator at a temperature of 4 ⁇ 8 °C for 10 days. The periodic control for presence of live bacteria is made.
- filtration as in example !
- the resulting three fractions are mixed in a volumetric ratio respectively 75 : 750 : 7500.
- fraction 1 - Preparation of fraction 1 - proceed in the manner described in example 1, where the suspension is diluted with distilled water to a concentration of 10 pkg/ml and then additionally diluted it with saline solution to a concentration of 0,001 pkg/ml.
- fraction 3 - Preparation of fraction 3 - proceed in the manner described in example 1, where the suspension is diluted with 5ml of saline solution, then the resulting suspension is treated by ultrasound for 10min and left it to stay in a refrigerator at a temperature of 4 - 8°C for 20 days, then is filtered as in example 1.
- Preparation of fraction 2 - proceed in the manner described in example 1
- Preparation of fraction 3 - proceed in the manner described in example 1, where the suspension is treated with ultrasound for 12 min, remained to stay at a temperature of 4 - 8°C for 40 days, then is filtered as in example 1.
- the obtained fractions are mixed in a ratio, respectively 1 : 10 : 100.
- fraction 1 - Preparation of fraction 1 - proceed in the manner described in example 1 , the suspension firstly is diluted with distilled water to a concentration of 20 pkg/ml and then diluted it additionally with saline solution to a concentration of 0,01 pkg/ml.
- fraction 3 - proceed in the manner described in example 1, where processing the resulting suspension is diluted with 4 ml of saline solution and treated with Ultrasound for 10 min and remained to stay at 4 - 8°C for 60 days.
- the obtained fractions 1, 2 and 3 are mixed in ratio, respectively 1 : 10 : 100.
- the submitted data concern the patients with different localisations of cancer diseases, male and female, without selection in age and stage of disease, who passed in a period of six months through all medical nationwide offices which use the composition in the country.
- the total of treated patients were 582.
- Figure 1 shows all past patients, grouped into 5 groups according to their survival time, after starting treatment with the agent according to the invention in years. As can be seen from the graph, most patients visited the offices for 5 and more years are 34.3%, followed by new patients - up to 1 year, which are 29.5%.
- Fig.1 On Fig.1 is indicated all treated patients divided in 5 groups according to their survival time, after beginning the therapy with the composition subject to the invention, in years. As shown on the graph, most are the patients who visited the consulting medical offices for 5 and more years, who are 34.3%, followed by the new patients - up to 1 year, who are 29.5%.
- the general survival rate over 3 years in monotherapy with the composition is 55.4%, i. e. more than half of the patients, irrespective the stage of their disease, treated only with the composition according to this invention, survive five and more than five years.
- Fig.1 Data of breast cancer patients are given in the next figure 2. It is understood that 95% of these patients are women, while men represent an insignificant percentage. According to world published data the most frequent localisation of cancer in women is breast cancer. The data of 284 patients are presented. The patients are treated with the composition subject to this invention, after completion of radio- and chemotherapy and irrespective of the intake of hormonal treatment depending on the hormonal status of the patients.
- Prostate cancer is ranked first and second in the world in localisation in men, immediately before or after lung cancer.
- the obtained results according to Fig. 4 are very promising, where almost 50% of the treated patients survive over 5 years and are considered healed according to medicine.
- Fig.5 includes the data of patients with ovarian cancer, endometrial cancer and uterine cancer. The patients were united because of the low number of patients with specific cancer localisations in female genitals. Apart from the varying course and forecasts for these diseases, the basic conclusion is that more than 5 years survival rate in this population is significant - more than 45%.
- the treatment with the composition subject to this invention is effective, easy to perform, without any adverse effect (hair loss, radiation complications, severe malaise etc.), sparing the body, inexpensive and providing long-lasting remission without recurrence and dissemination of the disease and providing normal and even comfortable way of life for the cancer patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method for obtaining of an anti-tumor composition with antitumor activity, as well as to a composition with antitumor activity, both of them based on the BCG vaccine and its use for prophylaxis and treatment of oncologic diseases. The method according to the present invention provides the obtaining of medications with differentiated impact of effect and allowing adequate dosing. The composition obtained by this method demonstrates reduced toxicity because of the low content of live bacteria and unexpectedly higher therapeutic effect than the already known one. This problem, according to the present invention is solved by method for preparation that includes the mixing of three fractions - fraction 1 containing live bacteria Mycobacterium bovis from BCG vaccine, fraction 2 consisting of suspension of killed bacteria Mycobacterium bovis from BCG vaccine, and fraction 3 that is a filtrate of a suspension of Mycobacterium bovis bacteria from BCG vaccine, destroyed by ultrasound, the fraction quantities being in a proportion of 1 : 10 : 100 volumetric units. The antitumour composition obtained by the method consisting the fraction 1 with live bacteria Mycobacterium bovis, fraction 2 consisting of suspension of killed bacteria Mycobacterium bovis and fraction 3 containing a filtrate of suspension of destroyed by ultrasound cells of Mycobacterium bovis bacteria in a volumetric proportion of 1 : 10 : 100, which contains not only live and killed bacteria but also parts of bacteria, bacterial cell walls, inner cytoplasmic membrane, enzymes, ribosomes, bacterial nuclei, wax D, proteins, carbohydrates, lipids and nucleic acids. The composition obtained by the present method is intended for the treatment of oncologic diseases that affect different organs and systems in the human body. The composition is especially suitable for prophylaxis of the occurrence of oncologic diseases in predisposed individuals and for prophylaxis to prevent recurrence.
Description
METHOD FOR OBTAINING OF AN ANTITUMOR COMPOSITION,
AN ANTITUMOR COMPOSITION
FIELD OF THE INVENTION
: '
The present invention relates to a method for obtaining of an antitumor composition from BCG vaccine, as well as to a composition with antitumor activity on the basis of BCG vaccine and use for prophylaxis and treatment of oncologic diseases thereof.
BACKGROUND OF THE INVENTION
EP 1 881 838 B1 discloses a method for preparing an antitumor composition by mixing two fractions obtained from a standard BCG vaccine containing Mycobacterium bovis, where fraction ^ containing live bacteria and obtained as a standard BCG vaccine containing 500 pg dried substance, is suspended in 1 mi of distilled water by first dilution of the suspension with saline solution or distilled water to a concentration from 100 to 10pkg/ml BCG, and second dilution of the suspension with saline solution to a concentration from 10 to 0,001 pkg/ml BCG, and fraction 2 is obtained by addition of standard solution of BCG vaccine to distilled water and additional dilution with saline solution, then the obtained suspension is treated with ultrasound for 8 - 12 minutes, allowed to stay at temperature of 4 - 8°C for 2 to 60 days, preferably 2 to 20 days, and then it is filtered. Both fractions are mixed in a
; i proportion from 0,01:1 to 1:0,01. The obtained composition is used for preparation of a medication for treatment of massive tumors, cancer of: throat, breast, stomach; liver, urinary bladder, colon, skin, as well as brain tumors, malignant melanoma and metastases of these cancers in all systems of the human body
TECHNICAL FIELD OF DISCLOSURE
The problem to be solved is the development of a method for preparation of an antitumor composition on the basis of BCG vaccine intended for treatment of oncologic diseases, with lower toxicity for better tolerance by the patients where the prepared composition possessing at least a similar antitumor activity with the live vaccine, and capable to ensure the obtaining
of preparations with controlled impact of effect, which provide the possibility for selection of a suitable agent for the individual need of the patient.
According to the present invention, this problem is solved by a method for preparation that includes the mixing of three fractions - fraction 1 containing live bacteria Mycobacterium bovis from BCG vaccine, fraction 2 consisting of suspension of killed bacteria Mycobacterium bovis from BCG vaccine, and fraction 3 that is a filtrate of a suspension of Mycobacterium bovis bacteria from BCG vaccine, destroyed by ultrasound, the fraction quantities being in a proportion of 1 : 10 : 100 volumetric units. The first stage of the present method is the obtaining of fraction 1 by dissolution of a standard ampoule of BCG vaccine in a standard solvent, additional dilution of the obtained suspension with saline solution or distilled water to a concentration of 100 to 10 pg/ml and a second dilution to a concentration of 10 to 0,001 pg/ml, following by preparation of fraction 2 through the heat treatment of a standard BCG vaccine, which is diluted with saline solution or distilled water to a concentration of 100 to 0,01 pg/ml and preparation of fraction 3 by dilution of a standard BCG vaccine with 3 to 5ml of saline solution or 4 to 6 ml of distilled water and treatment-of the suspension by ultrasound for 8 to 12 min, then the resulting suspension is remained for 2 to 60 days, preferably for 2 to 20 days at a temperature of 4 - 8°C, and then it is filtered.
Another subject of the present invention is an antitumor composition obtained by the method that comprises fraction 1 with live bacteria Mycobacterium bovis, fraction 2 consisting of a suspension of killed bacteria Mycobacterium bovis and fraction 3 containing a filtrate of a suspension of destroyed by ultrasound cells of Mycobacterium bovis bacteria in a volumetric proportion of 1 : 10 : 100, which contains not only live and killed bacteria but also parts of bacteria, bacterial cell walls, inner cytoplasmic membrane, enzymes, ribosomes, bacterial nuclei, wax D, proteins, carbohydrates, lipids and nucleic acids.
Another subject of the present invention is the composition use, obtained by the method for preparation of a medicinal composition, intended for treatment of oncologic diseases that affect different organs and systems in the human body. The composition is especially suitable for prophylaxis of the occurrence of oncologic diseases in predisposed individuals and for prophylaxis to prevent recurrence.
The advantage of the method according to the present invention is that it ensures the obtaining of medications with differentiated impact of effect and allowing adequate dosing, The composition obtained by this method demonstrates lower toxicity because of the low content of live bacteria and unexpectedly higher therapeutic effect than the already known composition .
The invention is illustrated by the following examples, which clarify it, without prejudice to the scope of its protection.
EXAMPLES I
Example 1
Preparation of fraction 1 - live BCG bacteria
One standard ampoule of BCG vaccine containing 500 pg of dried substance is suspended in 1ml of distilled water, the resulting suspension is diluted with saline solution to a concentration of 100 pkg/ml, then additionally is diluted by saline solution to reach a concentration of 10 pkg/ml. The content of living cells is controlled. Resulting fraction 1 contains in ddition to living cells, products of their vital activity and metabolites.
Preparation of fraction 2 - killed bacteria.
A standard ampoule of BCG vaccine is dissolved in saline solution or distilled water to a concentration of 100 pg/ml and subjected to heat treatment at 125° C and 1 ,5 atm for 20min. Fraction 2 contains in addition to killed bacteria, products of their vital activity, parts of cells, and metabolites.
Preparation of fraction 3 - filtrate
Standard ampoule of BCG vaccine is suspended in a standard solvent the resulting suspension is diluted with 3 ml of saline solution and treated with ultrasound for 8 min, then left to stay in a refrigerator at a temperature of 4 - 8° C for 48 hours. Control for the existence of live bacteria during the 1st and the 2nd day is made. The resulting suspension is further filtered through a sterile filter Falcon with <0,1 mm pore size. The obtained filtrate contains substances released by the cell during cell membrane destruction such as bacterial parts,
bacterial cell walls, inner cytoplasmic membrane, enzymes, ribosomes, bacterial nuclei, carbohydrates, lipids and nucleic acids.
The resulting three fractions are mixed in a volumetric ratio, respectively 5 : 50 : 500
I i
Example 2
Preparation of fraction 1 -proceed in the manner described in example 1 ,; where the resulting suspension is diluted in advance to a concentration of 50 pkg/ml and then to 0,1 pkg/ml.
Preparation of fraction 2 - proceed as in example 1, the working concentration is 11 m g/ml.
Preparation of fraction 3 - proceed in the manner described in example 1 , where the standard ampoule of BCG vaccine is dissolved with a standard solvent and the resulting suspension is diluted with 4 ml of distilled water. The resulting suspension is further treated by ultrasound for 9 min and left to stay in a refrigerator at a temperature of 4 ^ 8 °C for 10 days. The periodic control for presence of live bacteria is made. Followed by filtration as in example !
The resulting three fractions are mixed in a volumetric ratio respectively 75 : 750 : 7500.
Example 3
Preparation of fraction 1 - proceed in the manner described in example 1, where the suspension is diluted with distilled water to a concentration of 10 pkg/ml and then additionally diluted it with saline solution to a concentration of 0,001 pkg/ml.
Preparation of fraction 2 - proceed in the manner described in example 1 , the working concentration is 0,01 pkg/ml.
Preparation of fraction 3 - proceed in the manner described in example 1, where the suspension is diluted with 5ml of saline solution, then the resulting suspension is treated by ultrasound for 10min and left it to stay in a refrigerator at a temperature of 4 - 8°C for 20 days, then is filtered as in example 1.
The resulting fractions are mixed in a volumetric ratio respectively 5 : 50 : 500.
Example 4
Preparation of fraction 1 - proceed in the manner described in example 1.
it !
Preparation of fraction 2 - proceed in the manner described in example 1 Preparation of fraction 3 - proceed in the manner described in example 1, where the suspension is treated with ultrasound for 12 min, remained to stay at a temperature of 4 - 8°C for 40 days, then is filtered as in example 1.
The obtained fractions are mixed in a ratio, respectively 1 : 10 : 100.
Example 5
Preparation of fraction 1 - proceed in the manner described in example 1 , the suspension firstly is diluted with distilled water to a concentration of 20 pkg/ml and then diluted it additionally with saline solution to a concentration of 0,01 pkg/ml.
Preparation of fraction 2, with concentration of 0,1 pkg/ml.
Preparation of fraction 3 - proceed in the manner described in example 1, where processing the resulting suspension is diluted with 4 ml of saline solution and treated with Ultrasound for 10 min and remained to stay at 4 - 8°C for 60 days.
The obtained fractions 1, 2 and 3 are mixed in ratio, respectively 1 : 10 : 100.
Examples for application of the compositin and data of its effect
The submitted data concern the patients with different localisations of cancer diseases, male and female, without selection in age and stage of disease, who passed in a period of six months through all medical nationwide offices which use the composition in the country. The total of treated patients were 582.
Figure 1 shows all past patients, grouped into 5 groups according to their survival time, after starting treatment with the agent according to the invention in years. As can be seen from the graph, most patients visited the offices for 5 and more years are 34.3%, followed by new patients - up to 1 year, which are 29.5%.
On Fig.1 is indicated all treated patients divided in 5 groups according to their survival time, after beginning the therapy with the composition subject to the invention, in years. As
shown on the graph, most are the patients who visited the consulting medical offices for 5 and more years, who are 34.3%, followed by the new patients - up to 1 year, who are 29.5%.
The general survival rate over 3 years in monotherapy with the composition is 55.4%, i. e. more than half of the patients, irrespective the stage of their disease, treated only with the composition according to this invention, survive five and more than five years.
Considering the fact that patients in Tst and 2 nd stage of the disease were almost missing, this is a quite good indicator of healing.
Fig.1
Data of breast cancer patients are given in the next figure 2. It is understood that 95% of these patients are women, while men represent an insignificant percentage. According to world published data the most frequent localisation of cancer in women is breast cancer. The data of 284 patients are presented. The patients are treated with the composition subject to this invention, after completion of radio- and chemotherapy and irrespective of the intake of hormonal treatment depending on the hormonal status of the patients.
Fig.2
Data presented below concern colon cancer (sigma, rectum, anus etc.), given in Fig. 3. The obtained results are very similar to the previous ones, the survival of 5 and more years representing 34% of the patients. This is the second in frequency localisation of male and female cancer in the world.
Fig.3
Prostate cancer is ranked first and second in the world in localisation in men, immediately before or after lung cancer. The obtained results according to Fig. 4 are very promising, where almost 50% of the treated patients survive over 5 years and are considered healed according to medicine.
Fig.4
Fig.5 includes the data of patients with ovarian cancer, endometrial cancer and uterine cancer. The patients were united because of the low number of patients with specific cancer localisations in female genitals. Apart from the varying course and forecasts for these diseases, the basic conclusion is that more than 5 years survival rate in this population is significant - more than 45%.
Fig.5
For the patients with bladder cancer, the results presented in Fig. 6 about the 5-year survival rate are impressive (57,9%), almost 60%, which is a serious achievement taking into account the various stages of the disease of the monitored patients after multiple relapses and TURs and often with forthcoming total bladder extirpation.
Fig.6
The following human cancer localisations of the (cancer of throat, tongue, larynx and tonsils) also deserve attention according to Fig.7 and Fig.8 because of the high level of disabling conditions and bad prognostication, including the melanoma patients.
Fig.7 Fig.8
It is important to mention that the treatment with the composition subject to this invention is effective, easy to perform, without any adverse effect (hair loss, radiation complications, severe malaise etc.), sparing the body, inexpensive and providing long-lasting remission without recurrence and dissemination of the disease and providing normal and even comfortable way of life for the cancer patients.
Claims
1. Method for obtaining of an antitumor composition, comprising preparation of first fraction by dissolution of a standard ampoule of BCG vaccine in a standard solvent, additional dilution of the obtained suspension with saline solution or distilled water to a concentration of 100 to 10 pkg/ml, and second dilution to a concentration of 10 to 0,001 pkg/ml BCG, and preparation of another fraction by dilution of a standard BCG vaccine with 3 to 5 ml of saline solution or 4 to 6 ml of distilled water and treating of the suspension with ultrasound for 8 - 12 minutes, then the suspension is remained to stay for 2 to 60 days, preferably 2 to 20 days at a temperature of 4-8°C, and then it is filtered, characterising in that a fraction 1 containing live bacteria is prepared, a fraction 2 is prepared by heat processing of a standard BCG vaccine diluted to a concentration of 100 to 0,01 pkg/ml, and a fraction 3 is prepared, which is a filtrate of a suspension of bacteria destroyed by ultrasound, and all obtained three fractions are mixed in proportion of ratio respectively 1 : 10 : 100 volumetric units.
2. Antitumor composition obtained according to the method according to claim 1 , characterising in that the composition is consisting of the fraction 1 containing the live Mycobacterium bovis bacteria from BCG vaccine, fraction 2 containing the killed Mycobacterium bovis bacteria and fraction 3, which is a filtrate of a suspension of bacteria destroyed by ultrasound.
3. Use of an antitumor composition according to claims 1 and 2 for the manufacture of a medication for prophylaxis and treatment of oncologic diseases, especially Cancer of the throat, breast, stomach, liver, lungs, urinary bladder, colon, skin, brain tumors, genital cancer as well as metastases of such cancers in all organs and systems of the human body.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG113091A BG67525B1 (en) | 2020-02-25 | 2020-02-25 | Method of obtaining an agent with antitumour activity, an agent with antitumour activity, and use of the agent |
| PCT/BG2021/000008 WO2021168522A1 (en) | 2020-02-25 | 2021-02-11 | Method for obtaining of an antitumor composition, an antitumor composition and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4110379A1 true EP4110379A1 (en) | 2023-01-04 |
Family
ID=74884765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21712408.0A Pending EP4110379A1 (en) | 2020-02-25 | 2021-02-11 | Method for obtaining of an antitumor composition, an antitumor composition and its use |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4110379A1 (en) |
| BG (1) | BG67525B1 (en) |
| WO (1) | WO2021168522A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG66067B1 (en) * | 2005-05-18 | 2011-01-31 | Спартак ХАДЖИЕВ | Antitumour activity agent based on bcg vaccine, method of obtaining it and application thereof |
| EP2010216A4 (en) * | 2006-03-24 | 2010-06-09 | Donald L Morton | MYCOBACTERIAL IMMUNOTHERAPY FOR THE TREATMENT OF CANCER |
| ES2391108B1 (en) * | 2012-07-26 | 2013-10-07 | Universitat Autonoma De Barcelona | USE OF MYCOBACTERIUM BRUMAE FOR THE TREATMENT OF BLADDER CANCER |
-
2020
- 2020-02-25 BG BG113091A patent/BG67525B1/en unknown
-
2021
- 2021-02-11 EP EP21712408.0A patent/EP4110379A1/en active Pending
- 2021-02-11 WO PCT/BG2021/000008 patent/WO2021168522A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BG113091A (en) | 2021-08-31 |
| WO2021168522A1 (en) | 2021-09-02 |
| BG67525B1 (en) | 2023-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Macfarlane | Cancer of the Adrenal Cortex: The natural history, prognosis and treatment in a study of fifty-five cases. Hunterian Lecture delivered at the Royal College of Surgeons of England on 6th March 1958 | |
| Friedmann et al. | Wegener's granulomatosis causing deafness | |
| Graves et al. | Carcinoma of the male breast with axillary metastasis following stilbestrol therapy: report of a case treated by radical mastectomy | |
| EP1677811B1 (en) | Medicament on the basis of honey, preparation and use thereof | |
| EP4110379A1 (en) | Method for obtaining of an antitumor composition, an antitumor composition and its use | |
| WRIGHT et al. | Clinical evaluation of puromycin in human neoplastic disease | |
| Wallace | Effect of delayed addition of irradiated cells to small viable tumor inocula | |
| Kalra | Homoeopathy In Breast Cancer. | |
| RU2645957C1 (en) | Method of treatment of radiation injuries of bladder | |
| RU2112547C1 (en) | Medicinal composition for treatment of patients with malignant neoplasms | |
| CN114272290B (en) | A topical compound Chinese medicinal extract for treating cancer pain of all steps, and its preparation method | |
| CN101829167B (en) | A pharmaceutical composition for treating cervical erosion, and its preparation method | |
| Brunschwig | A review of the Wisconsin Cancer Institute | |
| EP1881838B1 (en) | Antitumor agent on the base of bcg vaccine, method for its preparation and its use | |
| Sangthawan et al. | Relapse in the skull after myeloablative therapy for high-risk neuroblastoma | |
| Coffey et al. | Extract of adrenal cortex substance: report of its preparation and use—with some clinical notes | |
| Jeppsson et al. | Carcinoma of the external ear | |
| Kamalam et al. | Nocardiosis: Two case reports | |
| Glucksmann | Changes produced in tissues by irradiation. | |
| Rosner et al. | Acute granulocytic leukemia in the elderly | |
| Martin et al. | Preliminary clinical and laboratory investigation of a chemotherapeutic agent in the treatment of brain tumors | |
| Hooton et al. | Conservation Therapy for Breast Cancer | |
| Corper | Pathologic Changes in Lung from Use of Mercurochrome-220 Soluble | |
| Howes et al. | Lymphosarcoma: a statistical study and evaluation of treatment | |
| Banerjee | Actinomycosis of the skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220914 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250120 |